Emetine hydrochloride - Acer Therapeutics
Alternative Names: ACER 2820; EmetineLatest Information Update: 16 Jun 2025
At a glance
- Originator Acer Therapeutics
- Class Antiprotozoals; Antivirals; Isoquinolines
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cytomegalovirus infections; Dengue; Ebola virus infections; Zika virus infection
- No development reported COVID 2019 infections
Most Recent Events
- 11 Jun 2025 Johns Hopkins University plans to initiate a phase II/III trial for Dengue in the US and Nepal (PO) (NCT07016321)
- 28 Jun 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (SC, Injection)
- 20 Nov 2023 Acer Therapeutics has been acquired by Zevra Therapeutics